Drug Profile
ICA 105665
Alternative Names: ICA-105665Latest Information Update: 04 Apr 2023
Price :
$50
*
At a glance
- Originator Icagen
- Developer Icagen, Inc.
- Class Antiepileptic drugs; Non-opioid analgesics; Small molecules
- Mechanism of Action KCNQ potassium channel agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Epilepsy; Neurological disorders; Pain
Most Recent Events
- 22 Feb 2023 Discontinued - Phase-I for Pain in United Kingdom (PO)
- 22 Feb 2023 Discontinued - Phase-I for Pain in USA (PO)
- 22 Feb 2023 Discontinued - Phase-II for Epilepsy in USA (PO)